PRODIGE 65-UCGI 36-GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma

Affiliation auteurs!!!! Error affiliation !!!!
TitrePRODIGE 65-UCGI 36-GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma
Type de publicationJournal Article
Year of Publication2020
Auteursde la Fouchardiere C., Hammel P., Launay S., Vienot A., Raimbourg J., Perrier H., Evesque L., Ghiringhelli F., Jary M., Aparicio T., Hocine F., Neuzillet C., Botsen D., Phelip J.M, Peytier A., Michel P., Cropet C., Lachaux N., Chabaud S., Dahan L.
JournalANNALS OF ONCOLOGY
Volume31
PaginationS954-S955
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.2049